SCHEMBL2149052

SCHEMBL2149052

O=c1[nH]c2ccccc2n1CCI

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.64
▸ HPGD P15428 2/20 0.64
▸ HTT P42858 2/20 0.64
▸ ALDH1A1 P00352 1/20 0.64
▸ MAPT P10636 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ POLB P06746 1/20 0.59
▸ HTR7 P34969 5/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ P2RX7 Q99572 1/20 0.51
▸ DAO P14920 1/20 0.50
▸ ACHE P22303 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318943 0.90 LMNA (0.69) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL2149671 0.88 LMNA (0.68) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL30947438 0.85 LMNA (0.78) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL6494898 0.82 LMNA (0.64) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL30546561 0.82 LMNA (0.64) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL763166 0.82 LMNA (0.64) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL891366 0.82 LMNA (0.64) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL961132 0.82 LMNA (0.64) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL21729878 0.82 LMNA (0.64) LMNAHPGDHTTALDH1A1MAPT
SCHEMBL29695523 0.82 CYP1A2 (0.74) LMNAHPGDHTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432420-B1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARM INC (US) 2011-07-13 — — EP disclosed
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2010-08-26 — — US disclosed
US-20080070948-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2008-03-20 — — US disclosed
US-20080009520-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2008-01-10 — — US disclosed
US-7300928-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS, INC. (US) 2007-11-27 — — US disclosed
US-7291611-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2007-11-06 — — US disclosed
US-7273857-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2007-09-25 — — US disclosed
US-20060258707-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-11-16 — — US disclosed
US-20060205785-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-09-14 — — US disclosed
US-20060199799-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-09-07 — — US disclosed
US-7087593-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2006-08-08 — — US disclosed
US-20060025402-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-02-02 — — US disclosed
US-6951849-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2005-10-04 — — US disclosed
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. 2004-04-08 — — US disclosed
US-20030100545-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS, INC. 2003-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070948-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 LMNA 3610/4885HPGD 2819/4885HTT 2865/4885
US-20030100545-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 LMNA 3578/4885HPGD 2776/4885HTT 3095/4885
US-20060258707-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 LMNA 3610/4885HPGD 2819/4885HTT 2865/4885
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 LMNA 3610/4885HPGD 2819/4885HTT 2865/4885
US-20060025402-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 LMNA 3610/4885HPGD 2819/4885HTT 2865/4885
US-20080009520-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 LMNA 3610/4885HPGD 2819/4885HTT 2865/4885
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 LMNA 3578/4885HPGD 2776/4885HTT 3095/4885
US-20060199799-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 LMNA 3610/4885HPGD 2819/4885HTT 2865/4885
US-20060205785-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 LMNA 3610/4885HPGD 2819/4885HTT 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback